OnDosis
Sofia (Fia) Ottemark has a diverse work experience spanning several roles and companies. Their most recent position is as a Senior Project Manager at OnDosis, a role they have held since August 2021. Prior to this, they worked at Mölnlycke for a significant portion of their career. Starting in 2005, they held various roles at Mölnlycke, including Global Product Manager, Technical Category Manager, Global Project Manager, Product Designer, R&D Product Developer, Laboratory Engineer, and Consultant within Microbiology. Sofia (Fia) worked on a range of projects and responsibilities within the wound care and business development sectors. Before joining Mölnlycke, Sofia briefly worked as a Molecular Biologist at the Department of Molecular Pharmacology at AstraZeneca from July 2005 to August 2005. Overall, Sofia has extensive experience in project management, product development, and microbiology within the healthcare industry.
Sofia (Fia) Ottemark began their education journey in 1999 at Chalmers University of Technology, where they pursued a Master of Science degree in Biotechnology. Their studies at Chalmers University lasted from 1999 to 2004.
In 2004, Sofia moved on to the Gothenburg Graduate School in Biomedicine (GGSB 2004) for postgraduate studies in Biomedical research. Sofia (Fia) completed their studies at the school in 2005.
After a significant gap in their education, Sofia enrolled in the IHM Business School in 2019. The specific degree name for this program is not provided, but Sofia focused their studies on Growth & Marketing Strategy. Their time at IHM Business School spanned only one year, from 2019 to 2019.
This person is not in any teams
OnDosis
1 followers
OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with asignificant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.